{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:56:54Z","timestamp":1786118214934,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05619-w","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:20:10Z","timestamp":1786029610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head in vitro susceptibility comparison of temocillin with amoxicillin\/clavulanate, piperacillin\/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital"],"prefix":"10.1007","author":[{"given":"Pushpa","family":"Saajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Candolesas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"vidushi.wickremeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayi","family":"Shali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Mulyanasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Karunasagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikandhini","family":"Visuvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"10325","key":"5619_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2019","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A et al (2019) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"5619_CR2","doi-asserted-by":"publisher","DOI":"10.2471\/B09585","volume-title":"Global antimicrobial resistance and use surveillance system (GLASS) report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. (2025) Global antimicrobial resistance and use surveillance system (GLASS) report 2025. Geneva: World Health Organization. Available at: https:\/\/www.who.int"},{"key":"5619_CR3","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. (2024) Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. ciae403 https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"4","key":"5619_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D van Duin","year":"2017","unstructured":"van Duin D, Doi Y (2017) The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8(4):460\u2013469. https:\/\/doi.org\/10.1080\/21505594.2016.1222343","journal-title":"Virulence"},{"issue":"4","key":"5619_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/antibiotics11040493","volume":"11","author":"T Lupia","year":"2022","unstructured":"Lupia T, De Benedetto I, Stroffolini G, Di Bella S, Mornese Pinna S, Zerbato V et al (2022) Temocillin: applications in antimicrobial stewardship as a potential carbapenem-sparing antibiotic. Antibiotics (Basel) 11(4):493. https:\/\/doi.org\/10.3390\/antibiotics11040493","journal-title":"Antibiotics (Basel)"},{"issue":"9","key":"5619_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/antibiotics14090859","volume":"14","author":"L Cosimi","year":"2025","unstructured":"Cosimi L, Zerbato V, GrasselliKmet N, Oliva A, CogliatiDezza F, Geremia N et al (2025) Temocillin: a narrative review of its clinical reappraisal. Antibiotics (Basel) 14(9):859. https:\/\/doi.org\/10.3390\/antibiotics14090859","journal-title":"Antibiotics (Basel)"},{"key":"5619_CR7","doi-asserted-by":"publisher","unstructured":"Enoch DA, Cargill JS, Laing K, Aliyu SH. (2022) Temocillin use as a carbapenem-sparing option in a UK teaching hospital for treating serious Gram-negative bacterial infections. JAC Antimicrob Resist. 4(5):dlac111. https:\/\/doi.org\/10.1093\/jacamr\/dlac111.","DOI":"10.1093\/jacamr\/dlac111"},{"key":"5619_CR8","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2025","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2025) Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0. Available at: https:\/\/www.eucast.org","edition":"Version 15.0"},{"key":"5619_CR9","volume-title":"Guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2017","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2017) Guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 2.0. Available at: https:\/\/www.eucast.org","edition":"Version 2.0"},{"key":"5619_CR10","unstructured":"UK Health Security Agency (2022) UK Standards for Microbiology Investigations B60: Investigation of \u03b2-lactam resistance mechanisms in Gram-negative bacteria. Issue 3.1. London: UK Health Security Agency"},{"key":"5619_CR11","doi-asserted-by":"publisher","unstructured":"Cogliati Dezza F, Barrera Pulido L, Borreguero I, Docobo P\u00e9rez F, Palomo Jim\u00e9nez V, de la Rosa Riestra S, et al. (2026) Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTART\u00c9): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial. Lancet. Published online. https:\/\/doi.org\/10.1016\/S0140-6736(26)00760-9.","DOI":"10.1016\/S0140-6736(26)00760-9"},{"issue":"2","key":"5619_CR12","doi-asserted-by":"publisher","first-page":"001955","DOI":"10.1099\/jmm.0.001955","volume":"74","author":"S Ali","year":"2025","unstructured":"Ali S, Tobin A, Lapthorne S, Collison M, Murphy D, Chan G et al (2025) Preserving the antimicrobial arsenal: exploring alternatives to carbapenems in ESBL battles within the southeast of Ireland. J Med Microbiol 74(2):001955. https:\/\/doi.org\/10.1099\/jmm.0.001955","journal-title":"J Med Microbiol"},{"issue":"6","key":"5619_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s10096-020-03844-5","volume":"39","author":"A Kuch","year":"2020","unstructured":"Kuch A, Wieczorek P, Sacha P et al (2020) Activity of temocillin against ESBL-, AmpC-, and\/or KPC-producing Enterobacterales isolated in Poland. Eur J Clin Microbiol Infect Dis 39(6):1185\u20131191. https:\/\/doi.org\/10.1007\/s10096-020-03844-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"5619_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jac\/dkl043","volume":"57","author":"DM Livermore","year":"2006","unstructured":"Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57(5):1012\u20131014. https:\/\/doi.org\/10.1093\/jac\/dkl043","journal-title":"J Antimicrob Chemother"},{"key":"5619_CR15","doi-asserted-by":"publisher","unstructured":"Stewart AG, Harris PNA, Henderson A, Paterson DL. (2022) Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO trial. JAC Antimicrob Resist. 4(1):dlab192. https:\/\/doi.org\/10.1093\/jacamr\/dlab192.","DOI":"10.1093\/jacamr\/dlab192"},{"key":"5619_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2026.06.021","author":"CC Lai","year":"2026","unstructured":"Lai CC, Liu CY, Hsueh SC, Huang YT, Hsueh PR, Jean SS (2026) Aztreonam-avibactam and cefiderocol against metallo-\u03b2-lactamase-producing Enterobacterales and other carbapenem-resistant Gram-negative pathogens: microbiological activity and clinical evidence. J Glob Antimicrob Resist. https:\/\/doi.org\/10.1016\/j.jgar.2026.06.021","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"5619_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2025","unstructured":"Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J et al (2025) Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis 25(2):218\u2013230. https:\/\/doi.org\/10.1016\/S1473-3099(24)00499-7","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5619_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf131","volume":"7","author":"GL Daikos","year":"2025","unstructured":"Daikos GL et al (2025) Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: a phase 3 randomized trial (ASSEMBLE). JAC-Antimicrob Resist 7(4):dlaf131. https:\/\/doi.org\/10.1093\/jacamr\/dlaf131","journal-title":"JAC-Antimicrob Resist"},{"issue":"2","key":"5619_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","volume":"31","author":"RA Bonnin","year":"2025","unstructured":"Bonnin RA, Jeannot K, Santerre Henriksen A, Quevedo J, Dortet L (2025) In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. Clin Microbiol Infect 31(2):240\u2013249. https:\/\/doi.org\/10.1016\/j.cmi.2024.09.031","journal-title":"Clin Microbiol Infect"},{"key":"5619_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896971","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Yang D, Wang Y, Ni W (2022) Cefiderocol for the treatment of multidrug-resistant Gram-negative bacteria: a systematic review of currently available evidence. Front Pharmacol 13:896971. https:\/\/doi.org\/10.3389\/fphar.2022.896971","journal-title":"Front Pharmacol"},{"issue":"2","key":"5619_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3103\/S0891416824700198","volume":"39","author":"W Yang","year":"2024","unstructured":"Yang W, Zhang Y, Wang X et al (2024) The effectiveness of aztreonam, aztreonam\u2013avibactam and cefiderocol on blaNDM-producing Escherichia coli isolates. Mol Genet Microbiol Virol 39(2):158\u2013164","journal-title":"Mol Genet Microbiol Virol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05619-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:20:12Z","timestamp":1786029612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05619-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":21,"alternative-id":["5619"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05619-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required as this project met NHS criteria for service evaluation. All data were anonymised before analysis.","order":1,"name":"Ethics","label":"Ethical","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}